CardioComm Solutions to Issue Shares for Debt and Issue Stock Options
- Wall St ends lower as investors await earnings, inflation data
- Microsoft (MSFT) announces $19.7 billion acquisition of Nuance (NUAN)
- Dollar drops as traders prepare for inflation data
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced the proposed issuance of shares and the issuance of stock options.
Under shares for debt agreements, the Company will issue an aggregate of 406,250 common shares of the Company ("Shares") to directors of the Company at a deemed price of $0.06 per Share. The Shares will be provided to settle debt for service expenses and will be subject to a four month hold period in accordance with applicable securities laws.
The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.06 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
To learn more about CardioComm's products and for further updates regarding HeartCheck" ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/79814
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bonterra Announces Stock Option Grant
- Hannon Armstrong Announces First Quarter 2021 Earnings Release Date and Conference Call
- Aberdeen Total Dynamic Dividend Fund Announces Monthly Distribution